Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged
NVOH
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 301 South State Street, Suite N-002 Newtown PA United States of America 18940
- IPO Date
- Jan 7, 2025
- Website
- precidianetfs.com
- Similar Companies
- Business
- Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) is an exchange-traded fund that provides U.S. investors with targeted exposure to the American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares), a Denmark-based multinational pharmaceutical company focused on diabetes, obesity care, and other healthcare products, while systematically hedging currency risk associated with the Danish krone through currency swaps and derivatives. The fund, under normal circumstances, invests at least 95% of its net assets in these ADRs and implements an integrated currency hedge mechanism managed by subadvisor CIBC, with custodian services from BNY Mellon and market making by GTS; it trades on the Cboe exchange under the ticker NVOH. Launched on January 2, 2025, and headquartered with Precidian Investments in New York, the ETF forms part of Precidian's innovative ADRhedged lineup targeting leading international companies. The fund offers focused equity exposure to Novo Nordisk A/S, which manufactures and markets core products including Wegovy, Semaglutide (GLP-1 receptor agonists for obesity and diabetes), long-acting basal insulins, and other pharmaceutical treatments for chronic conditions; it serves healthcare providers, patients, and institutional investors primarily in North America, Europe, and global markets. Precidian Funds LLC serves as the issuer and manager, emphasizing simplicity in ADR trading with built-in currency risk mitigation to enhance returns in a strong U.S. dollar environment. In recent developments, Precidian Investments launched NVOH in early January 2025 as one of four new ADRhedged ETFs, expanding its lineup to seven funds alongside siblings like AstraZeneca (AZNH), HSBC (HSBH), and Shell (SHEH), with plans for at least a dozen additional strategies in 2025 following SEC approval for 37 more. This expansion builds on Precidian's October 2024 debut of initial ADRhedged offerings and reflects strategic alliances with key service providers including CIBC for hedging oversight. The initiative targets U.S. investors seeking international single-stock exposure without unhedged foreign exchange volatility, amid growing demand for such currency-hedged solutions.